...FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 6-1 that Rejena from Lantibio did not demonstrate...
...U.S. rights to commercialize Rejena. TRB, which markets the product as Vismed in Europe, granted Lantibio...
...and market it to treat dry eye syndrome in 2006 (see BioCentury, Jan. 16, 2006). Lantibio...

...$0.45 (11%) to $4.69. The committee also voted 6-1 that Rejena (formerly Vismed ) from Lantibio...

...and Ophthalmic Drugs Advisory Committee will meet on June 26 to discuss an NDA from Lantibio...
...is a 0.18% sodium hyaluronate ophthalmic solution. TRB, which markets the product in Europe, granted Lantibio...
...U.S. rights to commercialize Vismed to treat dry eye syndrome (see BioCentury, Nov. 12, 2007). Lantibio...

...stem cell therapy delivered using plasma polymerization technology Nov 07 Lantibio/Alcon (NYSE:ACL)/ TRB Chemedica Undisclosed Lantibio...

...in Phase III testing for the indication. Lantibio plans to submit an NDA next year. Lantibio...
...also is eligible for royalties from Alcon. TRB, which markets the product in Europe, granted Lantibio...
...exclusive U.S. rights to develop and market Vismed in 2006 (see BioCentury, Jan. 16, 2006). Lantibio...

...year. AOP licensed the development rights from Lantibio. AOP Orphan Pharmaceuticals AG , Vienna, Austria Lantibio...

...FDA. Last year, Lantibio licensed Vismed from TRB Chemedica, which markets the product in Europe. Lantibio...

...TRB granted Lantibio exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome...
...to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio...
...of the sodium hyaluronate product in the U.S. this year. TRB markets Vismed in Europe. Lantibio...

...TRB Chemedica (Geneva, Switzerland) granted Lantibio (Chapel Hill, N.C.) exclusive U.S. rights to develop and market...
...to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio...
...of the sodium hyaluronate product in the U.S. this year. TRB markets Vismed in Europe. Lantibio...

...Apotex will produce clinical and commercial batches of Lantibio's Moli1901 in exchange for royalties. The polycyclic...
...antibiotic is in Phase I testing to treat dry eye syndrome and cystic fibrosis (CF). Lantibio Inc....